Kuldeep Singh
About Kuldeep Singh
Kuldeep Singh serves as the Senior Director and Head of Pathology in Preclinical Development at Wave Life Sciences, bringing extensive experience in toxicologic pathology and advanced techniques in data interpretation. He previously held positions at Sanofi Genzyme and the University of Illinois at Urbana-Champaign, and has a strong academic background in pathology and molecular pathology.
Work at Wave Life Sciences
Kuldeep Singh currently holds the position of Senior Director, Head of Pathology, Preclinical Development at Wave Life Sciences. He has been with the company since 2021, contributing to the advancement of preclinical development processes. His role involves overseeing pathology functions and ensuring the integration of pathology data into the drug development pipeline. Singh's expertise in preclinical safety assessments and investigative pathology supports the company's efforts in developing innovative therapies.
Previous Experience at Sanofi Genzyme
Prior to his role at Wave Life Sciences, Kuldeep Singh worked at Sanofi Genzyme as a Principal Scientist/Pathologist from 2015 to 2020. During his five years in Framingham, he focused on pathology-related research and contributed to the development of therapeutic strategies. His experience at Sanofi Genzyme enhanced his skills in toxicologic pathology and preclinical safety assessments.
Academic Background and Teaching Experience
Kuldeep Singh has a solid academic background, having served as an Associate Professor of Anatomic Pathology at the University of Illinois at Urbana-Champaign from 2008 to 2015. In this role, he was involved in teaching and mentoring students in the field of pathology. He also worked as a Lecturer at Oklahoma State University from 2005 to 2007, further contributing to education in the discipline.
Education and Expertise in Pathology
Kuldeep Singh's educational journey includes a BVSc & AH degree from G.B. Pant University of Agriculture and Technology, followed by an MS in Pathology/Experimental Pathology from Utrecht University. He completed his PhD in Molecular Pathology at Oklahoma State University. His training has equipped him with advanced skills in quantitative digital pathology, immunohistochemistry, and transmission electron microscopy, which he applies in his current and previous roles.
Specialization in Preclinical Development
Kuldeep Singh specializes in preclinical development, particularly in conducting safety assessments for both GLP and non-GLP toxicologic pathology. He serves as a pathology representative for small molecules and biologics, utilizing his extensive experience in investigative pathology. His work focuses on target identification, validation, lead candidate optimization, and biomarker assessment, which are critical for the success of drug development initiatives.